Bristol-Myers Squibb Co. (BMY)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$0.53 (-0.90%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Bristol-Myers Squibb Co. (BMY)
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Key Insights

Critical company metrics and information
  • Share Price

    $58.71
  • Market Cap

    $119.07 Billion
  • Total Outstanding Shares

    2.03 Billion Shares
  • Total Employees

    34,100
  • Dividend

    $0.6 Per Share Quarterly
  • IPO Date

    June 23, 1952
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.bms.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$-22.50 Billion
Net Cash Flow From Operating Activities$15.00 Billion
Net Cash Flow From Financing Activities, Continuing$7.74 Billion
Net Cash Flow From Financing Activities$7.74 Billion
Net Cash Flow From Investing Activities, Continuing$-22.50 Billion
Net Cash Flow From Operating Activities, Continuing$15.00 Billion
Exchange Gains/Losses$88.00 Million
Net Cash Flow$325.00 Million
Net Cash Flow, Continuing$237.00 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Diluted Average Shares$2.01 Billion
Diluted Earnings Per Share$-3.58
Income/Loss Before Equity Method Investments$-6.84 Billion
Income/Loss From Equity Method Investments$11.00 Million
Operating Income/Loss$-6.88 Billion
Income Tax Expense/Benefit, Deferred$-2.63 Billion
Income/Loss From Continuing Operations Before Tax$-6.88 Billion
Cost Of Revenue$11.90 Billion
Benefits Costs and Expenses$54.31 Billion
Income/Loss From Continuing Operations After Tax$-7.25 Billion
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Preferred Stock Dividends And Other Adjustments$0.00
Net Income/Loss Attributable To Parent$-7.26 Billion
Basic Average Shares$2.01 Billion
Research and Development$10.45 Billion
Net Income/Loss Attributable To Noncontrolling Interest$11.00 Million
Basic Earnings Per Share$-3.58
Gross Profit$35.53 Billion
Costs And Expenses$54.31 Billion
Selling, General, and Administrative Expenses$8.35 Billion
Operating Expenses$42.41 Billion
Net Income/Loss$-7.25 Billion
Net Income/Loss Available To Common Stockholders, Basic$-7.26 Billion
Income Tax Expense/Benefit$367.00 Million
Revenues$47.44 Billion
Other Operating Expenses$23.62 Billion

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Intangible Assets$26.96 Billion
Liabilities$76.47 Billion
Other Current Assets$13.72 Billion
Other Current Liabilities$17.89 Billion
Assets$93.67 Billion
Current Assets$28.07 Billion
Equity Attributable To Parent$17.14 Billion
Noncurrent Assets$65.59 Billion
Noncurrent Liabilities$53.83 Billion
Current Liabilities$22.64 Billion
Other Non-current Liabilities$4.29 Billion
Accounts Payable$3.47 Billion
Inventory$3.33 Billion
Long-term Debt$49.55 Billion
Wages$1.28 Billion
Accounts Receivable$11.03 Billion
Equity Attributable To Noncontrolling Interest$58.00 Million
Equity$17.20 Billion
Fixed Assets$6.90 Billion
Other Non-current Assets$31.73 Billion
Liabilities And Equity$93.67 Billion

Historical Dividends

Current dividend: $0.6 Per Share Quarterly
Announcement DatePayment DateRecord DateAmountFrequency
Sep 10, 2024Nov 1, 2024Oct 4, 2024$0.6Quarterly
Jun 18, 2024Aug 1, 2024Jul 5, 2024$0.6Quarterly
Mar 1, 2024May 1, 2024Apr 5, 2024$0.6Quarterly
Dec 6, 2023Feb 1, 2024Jan 5, 2024$0.6Quarterly
Sep 20, 2023Nov 1, 2023Oct 6, 2023$0.57Quarterly
Jun 14, 2023Aug 1, 2023Jul 7, 2023$0.57Quarterly
Mar 3, 2023May 1, 2023Apr 10, 2023$0.57Quarterly
Dec 8, 2022Feb 1, 2023Jan 6, 2023$0.57Quarterly
Sep 14, 2022Nov 1, 2022Oct 7, 2022$0.54Quarterly
Jun 15, 2022Aug 1, 2022Jul 1, 2022$0.54Quarterly
Mar 1, 2022May 2, 2022Apr 1, 2022$0.54Quarterly
Dec 13, 2021Feb 1, 2022Jan 7, 2022$0.54Quarterly
Sep 9, 2021Nov 1, 2021Oct 1, 2021$0.49Quarterly
Jun 17, 2021Aug 2, 2021Jul 2, 2021$0.49Quarterly
Mar 1, 2021May 3, 2021Apr 1, 2021$0.49Quarterly
Dec 10, 2020Feb 1, 2021Jan 4, 2021$0.49Quarterly
Sep 10, 2020Nov 2, 2020Oct 2, 2020$0.45Quarterly
Jun 11, 2020Aug 3, 2020Jul 6, 2020$0.45Quarterly
Mar 2, 2020May 1, 2020Apr 3, 2020$0.45Quarterly
Dec 5, 2019Feb 3, 2020Jan 3, 2020$0.45Quarterly
Sep 11, 2019Nov 1, 2019Oct 4, 2019$0.41Quarterly
Jun 13, 2019Aug 1, 2019Jul 5, 2019$0.41Quarterly
Mar 7, 2019May 1, 2019Apr 5, 2019$0.41Quarterly
Dec 6, 2018Feb 1, 2019Jan 4, 2019$0.41Quarterly
Sep 12, 2018Nov 1, 2018Oct 5, 2018$0.4Quarterly
Jun 14, 2018Aug 1, 2018Jul 6, 2018$0.4Quarterly
Mar 1, 2018May 1, 2018Apr 6, 2018$0.4Quarterly
Dec 7, 2017Feb 1, 2018Jan 5, 2018$0.4Quarterly
Sep 13, 2017Nov 1, 2017Oct 6, 2017$0.39Quarterly
Jun 13, 2017Aug 1, 2017Jul 7, 2017$0.39Quarterly
Mar 2, 2017May 1, 2017Apr 7, 2017$0.39Quarterly
Dec 8, 2016Feb 1, 2017Jan 6, 2017$0.39Quarterly
Aug 3, 2016Nov 1, 2016Oct 7, 2016$0.38Quarterly
Jun 7, 2016Aug 1, 2016Jul 1, 2016$0.38Quarterly
Mar 3, 2016May 2, 2016Apr 1, 2016$0.38Quarterly
Dec 8, 2015Feb 1, 2016Jan 4, 2016$0.38Quarterly
Sep 17, 2015Nov 2, 2015Oct 2, 2015$0.37Quarterly
Jun 16, 2015Aug 3, 2015Jul 6, 2015$0.37Quarterly
Mar 2, 2015May 1, 2015Apr 6, 2015$0.37Quarterly
Dec 9, 2014Feb 2, 2015Jan 2, 2015$0.37Quarterly
Sep 16, 2014Nov 3, 2014Oct 3, 2014$0.36Quarterly
Jun 17, 2014Aug 1, 2014Jul 3, 2014$0.36Quarterly
Mar 3, 2014May 1, 2014Apr 4, 2014$0.36Quarterly
Dec 19, 2013Feb 3, 2014Jan 3, 2014$0.36Quarterly
Sep 17, 2013Nov 1, 2013Oct 4, 2013$0.35Quarterly
Jun 19, 2013Aug 1, 2013Jul 5, 2013$0.35Quarterly
Mar 7, 2013May 1, 2013Apr 5, 2013$0.35Quarterly
Dec 4, 2012Feb 1, 2013Jan 4, 2013$0.35Quarterly

Related Companies

View additional S&P 500 companies similar to Bristol-Myers Squibb Co. (BMY)
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.